Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| 2,5-Dioxopyrrolidin-1-yl 3-(tritylthio)propanoate | 2,5-Dioxopyrrolidin-1-yl 3-(tritylthio)propanoate, a multifaceted chemical compound, plays a pivotal role in drug synthesis, specifically in the development of angiotensin converting enzyme inhibitors. In addition to its significance in this domain, it functions as a valuable building block in drug development for maladies such as hypertension, heart failure, and diabetes. Its diverse utilization and multifarious potential thereby make it a crucial focus of drug research. Group: Pharmaceutical. CAS No. 129431-12-5. Pack Sizes: 1 g. Product ID: B0001-286444. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| Amrinone | Amrinone is a selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. It is a simple, non-glycoside cardiotonic agent. It provides protection against ischemia-reperfusion injury in kidney, liver, and heart. It has the ability to stimulate calcium ion influx into the cardiac cell. It is used in the treatment of congestive heart failure. It increases cardiac contractility as a vasodilator. It acts by inhibiting the breakdown of both cAMP and cGMP by the phosphodiesterase (PDE3) enzyme. It is a drug that may improve the prognosis in patients with congestive heart failure. It has been shown to increase the contractions initiated in the heart by high gain calcium induced calcium release (CICR). It was developed by Sanofi and has been listed. Uses: Amrinone is a simple, non-glycoside cardiotonic agent. it provides protection against ischemia-reperfusion injury in kidney, liver, and heart. it is used in the treatment of congestive heart failure. it increases cardiac contractility as a vasodilator. Group: Pharmaceutical. CAS No. 60719-84-8. Pack Sizes: 2.5 g. Product ID: B0084-072903. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Captopril disulfide | A metabolite of Captopril, an orally active angiotensin-converting enzyme (ACE) inhibitor used in the treatment of hypertension and congestive heart failure. Group: Pharmaceutical. CAS No. 64806-05-9. Pack Sizes: 100 mg. Product ID: B1370-468095. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Enalapril EP Impurity D | An impurity of Enalapril. Enalapril is an angiotensin-converting-enzyme inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure. Group: Pharmaceutical. CAS No. 115729-52-7. Pack Sizes: 500 mg. Product ID: B2694-470980. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Enalapril EP Impurity G | An impurity of Enalapril. Enalapril is an angiotensin-converting-enzyme inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure. Group: Pharmaceutical. CAS No. 460720-14-3. Pack Sizes: 100 mg. Product ID: B2694-470982. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Isopropyl 4-[4-[N,N-bis(2-hydroxyethyl)amino]phenyl]butyrate | Isopropyl 4-[4-[N,N-bis(2-hydroxyethyl)amino]phenyl]butyrate, a pharmaceutical intermediate, can be utilized in the production of drugs intended for the treatment of cardiovascular disease, such as hypertension. It functions as an angiotensin-converting enzyme (ACE) inhibitor, which reduces the likelihood of heart attack and stroke by regulating blood pressure levels. Consequently, it plays a valuable role in managing these serious medical conditions, thus improving overall health outcomes among patients. Group: Pharmaceutical. CAS No. 94086-78-9. Pack Sizes: 10 mg. Product ID: B2699-045702. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Lisinopril Impurities | Lisinopril Impurities refer to compounds related to the angiotensin-converting enzyme (ACE) inhibitor Lisinopril, used in the management of hypertension and heart failure. These impurities are crucial in ensuring the efficacy and safety of Lisinopril by facilitating the quality control and refinement processes in pharmaceutical manufacturing. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ramipril | Ramipril is a second generation angiotensin-converting enzyme (ACE) inhibitor that acts as a prodrug, which is hydrolyzed in vivo to the active metabolite ramiprilat. It is used in treatment of congestive heart failure, hypertension and heart attacks. It is also useful in preventing renal and retinal complications in diabetes. It was developed by Pfizer and has been listed. Uses: Ramipril is used in treatment of congestive heart failure, hypertension and heart attacks. it is also useful in preventing renal and retinal complications in diabetes. Group: Pharmaceutical. CAS No. 87333-19-5. Pack Sizes: 10 g. Product ID: B0084-140017. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ramipril EP Impurity A | An impurity of Ramipril, an angiotensin-converting enzyme inhibitor used to treat hypertension and congestive heart failure. Group: Pharmaceutical. CAS No. 108313-11-7. Pack Sizes: 100 mg. Product ID: B1370-303999. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ruboxistaurin HCl | Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-maximal inhibitory constant of 4.5 and 5.9 nM, respectively. The half-life of ruboxistaurin, which can be orally administered, is approximately 9h and that of its metabolite 16h, therefore allowing once-daily dosing. Based on data from clinicalTrials.gov, Children's Hospital Medical Center, Cincinnati plan a phase I/II trial of the effect of ruboxistaurin for its safety, tolerability, and effectiveness in treating adult patients with heart failure on June 9, 2016. Uses: Enzyme inhibitors. Group: Pharmaceutical. CAS No. 169939-93-9. Pack Sizes: 10 mg. Product ID: B0084-263880. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Sacubitril | Sacubitril, also known as AHU377 or LCZ696, is an angiotensin receptor neprilysin inhibitor being studied for use in combination with valsartan for heart failure. Sacubitril is a prodrug that is activated to LBQ657 by de-ethylation via esterases. LBQ657 inhibits the enzyme neprilysin, which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure lowering peptides that work mainly by reducing blood volume. Group: Pharmaceutical. CAS No. 149709-62-6. Pack Sizes: 10 g. Product ID: B0084-458470. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
